📊 MBRX Key Takeaways
Is Moleculin Biotech, Inc. (MBRX) a Good Investment?
Moleculin Biotech is a pre-revenue pharmaceutical company burning through cash with no commercially viable products generating revenue. The company is operating at significant losses with negative cash flow of $22.7M annually, while cash reserves of $8.9M provide only 4-5 months of runway at current burn rates, creating critical liquidity concerns.
Moleculin Biotech’s fundamentals are very weak: it has no revenue, deeply negative operating and net income, and negative free cash flow with no evidence of commercial scale. While the balance sheet has no meaningful debt and still shows positive equity, the current cash balance appears insufficient relative to annual operating cash burn, making future dilution or financing dependence a major risk.
Why Buy Moleculin Biotech, Inc. Stock? MBRX Key Strengths
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Adequate current ratio of 1.41x suggesting near-term liquidity coverage for current liabilities
- Low capital expenditure requirements ($0M) allowing cash preservation for operations
- Debt-free capital structure reduces financial leverage risk
- Positive stockholders’ equity provides some balance sheet support
- Current ratio above 1.0 indicates near-term obligations are currently covered
MBRX Stock Risks: Moleculin Biotech, Inc. Investment Risks
- Critical burn rate of $22.7M annually with only ~5 months of cash runway remaining
- Zero revenue generation indicates no commercialized products or viable business model
- Severely negative returns (ROE -223.6%, ROA -151.7%) demonstrating value destruction
- Continued massive operating losses ($25.1M) with negative net income of $33.6M unsustainable
- No insider buying activity in last 90 days suggests lack of confidence from management
- No revenue base means the business is entirely dependent on external financing and pipeline execution
- Large recurring operating and free cash flow losses suggest limited cash runway
- Very weak returns on assets and equity indicate poor current capital efficiency
Key Metrics to Watch
- Cash balance depletion rate and timeline to cash runway exhaustion
- Revenue generation milestones from clinical trials or product commercialization
- Monthly operating burn rate and any evidence of cost reduction initiatives
- Funding announcements or capital raises to extend runway
- Clinical trial progress and regulatory approval status for pipeline candidates
- Quarterly operating cash burn versus cash and equivalents
- Any transition from zero revenue to partnership, licensing, or product revenue
Moleculin Biotech, Inc. (MBRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Moleculin Biotech, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MBRX Profit Margin, ROE & Profitability Analysis
MBRX vs Healthcare Sector: How Moleculin Biotech, Inc. Compares
How Moleculin Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Moleculin Biotech, Inc. Stock Overvalued? MBRX Valuation Analysis 2026
Based on fundamental analysis, Moleculin Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Moleculin Biotech, Inc. Balance Sheet: MBRX Debt, Cash & Liquidity
MBRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Moleculin Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-189.14 indicates the company is currently unprofitable.
MBRX Revenue Growth, EPS Growth & YoY Performance
MBRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.9M | $-0.63 |
| Q2 2025 | N/A | -$4.3M | $-0.49 |
| Q1 2025 | N/A | -$5.0M | $-0.69 |
| Q3 2024 | N/A | -$4.3M | $-2.82 |
| Q2 2024 | N/A | -$4.3M | $-1.70 |
| Q1 2024 | N/A | -$5.0M | $-2.02 |
| Q3 2023 | N/A | -$5.6M | $-0.19 |
| Q2 2023 | N/A | -$6.0M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Moleculin Biotech, Inc. Dividends, Buybacks & Capital Allocation
MBRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Moleculin Biotech, Inc. (CIK: 0001659617)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBRX
What is the AI rating for MBRX?
Moleculin Biotech, Inc. (MBRX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBRX's key strengths?
Claude: Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk. Adequate current ratio of 1.41x suggesting near-term liquidity coverage for current liabilities. ChatGPT: Debt-free capital structure reduces financial leverage risk. Positive stockholders’ equity provides some balance sheet support.
What are the risks of investing in MBRX?
Claude: Critical burn rate of $22.7M annually with only ~5 months of cash runway remaining. Zero revenue generation indicates no commercialized products or viable business model. ChatGPT: No revenue base means the business is entirely dependent on external financing and pipeline execution. Large recurring operating and free cash flow losses suggest limited cash runway.
What is MBRX's revenue and growth?
Moleculin Biotech, Inc. reported revenue of $0.0.
Does MBRX pay dividends?
Moleculin Biotech, Inc. does not currently pay dividends.
Where can I find MBRX SEC filings?
Official SEC filings for Moleculin Biotech, Inc. (CIK: 0001659617) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBRX's EPS?
Moleculin Biotech, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Moleculin Biotech, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBRX stock overvalued or undervalued?
Valuation metrics for MBRX: ROE of -223.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBRX stock in 2026?
Our dual AI analysis gives Moleculin Biotech, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBRX's free cash flow?
Moleculin Biotech, Inc.'s operating cash flow is $-22.7M, with capital expenditures of $0.0.
How does MBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -223.6% (avg: 15%), current ratio 1.41 (avg: 2).